CliffBio
small molecule

KYGEVVI

DOXECITINE; DOXRIBTIMINE

Loss of exclusivityAugust 2040latest FDA-listed patent expiry
CompanyUCB →See this company's full patent-cliff portfolio

Drug detail

Brand nameKYGEVVI
Active ingredientDOXECITINE; DOXRIBTIMINE
Strength2GM/PACKET;2GM/PACKET
Dosage formFOR SOLUTION
RouteORAL
ModalitySmall molecule
FDA approvalNovember 2025
Marketing statusRX

Listed patents

PatentExpiresType
11649259August 2040product
10471087August 2036use U-4358

Regulatory exclusivity

CodeExpires
NCENovember 2030

More from UCB

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.